Sharemaestro Newsreel

Richard Griffiths (SLN) reports 14.39M-share beneficial stake in Silence Therapeutics

Richard Griffiths has updated his beneficial ownership in Silence Therapeutics plc, reporting a 7.97% stake, or 14,391,498 ordinary shares. This amendment (Amendment No. 11) reflects significant dilution due to an increase in the issuer's share capital and includes the sale of 5,484,320 ADSs by …

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT)

Two healthcare companies, Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT), recently received bullish ratings from analysts. Myles Minter from William Blair reiterated a Buy rating for Alto Neuroscience, with a consensus price target of $35.71. Jonna Kim from TD Cowen also reiterated a Buy …

X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026)

This article reports on an SEC Form 144 filing by X4 Pharmaceuticals, Inc. (XFOR) on August 13, 2026. The filing indicates a proposed sale of 24,576 shares of common stock with an aggregate market value of $111,943.68, acquired through restricted stock unit vesting. The …

MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS

MediWound (NASDAQ:MDWD) Issues Earnings Results

Caribou Biosciences earnings beat by $0.07, revenue topped estimates

US Stock Futures Flat After S&P500, Dow End At Record Highs On Strong Earnings, Easing Geopolitical Concerns — PLTR, AZN, CMG, MRNA In Focus

Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS) reported a quarterly loss of $0.40 per share, missing analysts' consensus estimates by $0.06. The stock traded down to $3.01 with a market capitalization of $190.68 million, but analyst sentiment remains a "Moderate Buy" with a $7.50 target price. Institutional investors …

Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results

Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …

GERN|Geron Corp|Price:1.530|Chg%:-0.040

This article provides a detailed overview of Geron Corp (GERN) stock performance, financial data, and analyst ratings. It highlights the company's current stock price, market capitalization, key financial figures, and a "Buy" consensus rating from analysts with a significant upside potential. The profile section …

Xenon Pharmaceuticals Director Sold Shares Worth Over $640K

Steven Gannon, a Director at Xenon Pharmaceuticals (XENE), reported the sale of common shares totaling $640,550 on August 11, 2026. The transactions were executed at a weighted-average price of $64.055 per share. Following this sale, Gannon directly holds 1,870 common shares in the company.

Tango Therapeutics (TNGX) Is Getting Fresh Attention, What Are Investors Looking At?

Tango Therapeutics (TNGX) recently saw investor attention due to a wider Q2 net loss, the cessation of collaboration revenue, and a new US$400 million at-the-market equity offering which could dilute shareholders. Despite short-term share price drops, the stock shows strong momentum over longer periods, …

MediciNova: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for MediciNova. No further details are available in the provided content.

Wave Life Sciences (WVE) director’s 3,864-share tax sale under 10b5-1 plan

Ken Takanashi, a director at Wave Life Sciences (WVE), sold 3,864 shares of common stock on August 11, 2026, at a weighted-average price of $6.01 per share. This sale was made under a Rule 10b5-1 trading plan solely to cover tax obligations arising from …

Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA

This article provides a financial overview of Zevra Therapeutics, Inc. (FWB:1GDA) on the Frankfurt Stock Exchange, focusing on its price-to-earnings forward metric. It highlights that the market is currently closed with no trades. The content is sourced from FactSet and ICE Data Services.

Innate Pharma Seeks to Raise EUR23 Million from Share Offering

Innate Pharma is looking to raise EUR23 million through a share offering. This announcement comes after several recent developments, including an upgrade to Outperform by Leerink Partners, and a strategic partnership with Swedish Orphan Biovitrum AB for their drug Lacutamab, which is advancing to …

MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

MiNK Therapeutics (NASDAQ:INKT) reported a quarterly EPS loss of $0.62, missing analyst estimates by $0.02. The company advanced its agenT-797 treatment into a randomized Phase II ARDS trial, with preliminary data expected in the first half of 2027, and launched a paid named-patient access …

(XNCR) as a Liquidity Pulse for Institutional Tactics

This article analyzes Xencor Inc. (NASDAQ: XNCR) based on AI models, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored …

Verrica (VRCA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jayson RiegerChief Medical Officer - Noah RosenbergInterim Chief Financial Officer - John KirbyChief Operating Officer - David ZawitzChief Commercial Officer - Chris …

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.16 EPS

Edesa Biotech (NASDAQ:EDSA) reported a quarterly loss of $0.60 per share, missing analyst expectations by $0.16. Shares traded up $0.13 to $5.43, with a highly volatile one-year range of $0.72 to $20.32. Institutional investors own 5.50% of the stock, and analyst ratings are mixed, …

Equillium (NASDAQ:EQ) Announces Earnings Results

Cibus updates Latin America rice launch to 2028 while outlining $20M-$40M biofragrance revenue opportunity

Earnings Call Insights: Cibus, Inc. (CBUS) Q2 2026 MANAGEMENT VIEW * CEO Craig Wichner framed his priorities around scaling revenue and tighter spending control, saying, "I accepted the job of CEO because I believe we can generate revenue at scale. That is my mission." …

Invivyd earnings missed by $0.03, revenue fell short of estimates

Invivyd (NASDAQ: IVVD) reported second-quarter EPS of $-0.140, missing analyst estimates by $0.03, and revenue of $14.29M, falling short of the $15.64M consensus. The company's stock price has declined by -43.310% over the last three months and -2.980% over the last twelve months. Despite …

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …

Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million

Cadrenal Therapeutics (NASDAQ: CVKD) reported a Q2 2026 net loss of $3.3 million, an improvement from $3.7 million in the prior year, primarily due to reduced R&D expenses. The company ended the quarter with $2.4 million in cash, which increased to $4.2 million in …

Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN) reported a quarterly loss of $0.27 per share, missing the consensus estimate by $0.11. The stock subsequently fell 1.9% to $3.70, with a consensus "Hold" rating and an average price target of $9.67 from analysts. Institutional investors hold a significant portion …

Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results

Replimune Group (NASDAQ:REPL) reported a Q1 loss of $0.72 per share, missing analyst estimates. Despite the earnings miss and ongoing litigation, the company's shares fell by 1.4% to $14.97, and it expects to launch TUDRIQEV™ (RP1) for advanced melanoma within 60 days following FDA …

Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares

Altimmune Inc.'s President and CEO, Jerome Durso, recently purchased 15,000 shares of the company's stock, increasing his direct ownership to 62,500 shares. This transaction is part of a larger trend of insider buying at Altimmune, with 11 insider buys and no sells in the …

Dare Bioscience earnings beat by $0.11, revenue topped estimates

Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of $-0.2000, surpassing analyst estimates by $0.11, and revenue of $187.55K, significantly beating the consensus estimate of $1.67K. Despite the positive earnings surprise, the company's stock has seen a decline of -36.87% over the last three months …

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares of Stock

Top Kailera Therapeutics (KLRA) Competitors 2026

Arcturus (ARCT) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported strong Q2 2026 results, with net product revenue of $25.1 million and total revenue of $40.1 million. The company secured $75 million in non-dilutive royalty financing and a $15 million milestone payment, extending its cash runway into the second half of …